AstraZeneca suspends share repurchase programme

RNS Number : 6025N

AstraZeneca PLC

01 October 2012

 



ASTRAZENECA SUSPENDS SHARE REPURCHASE PROGRAMME,

CORE EPS TARGET IN THE RANGE OF $6.00 AND $6.30 UNCHANGED

AstraZeneca today announced that it is suspending share repurchases with immediate effect.  During 2012 the company has completed net share repurchases of $2.3 billion in respect of its initial target of $4.5 billion.

AstraZeneca confirms its Core EPS target range for the Full Year 2012 is maintained at $6.00 to $6.30.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the Board and I complete the company's ongoing annual strategy update." 

In line with usual practice, AstraZeneca will update the market on the outlook for 2013 in conjunction with the Full Year 2012 Financial Results announcement in January.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries UK

Esra Erkal-Paler                     [phone]

Sarah Lindgreen                     [phone]

Media Enquiries Sweden

Ann-Leena Mikiver                   [phone]

Investor Enquiries UK
James Ward-Lilley Karl Hård	[phone] [phone]	mob: [phone] mob: [phone]
Nicklas Westerholm US	[phone]	mob: [phone]

1^st October 2012                    

-     ENDS  -

 

END

 

 

MSCBKDDQDBDDBKK